The American Journal of Medicine
Volume 121, Issue 11 , Pages 935-942 , November 2008

Epidemiology of Venous Thromboembolism in Cardiorespiratory and Infectious Disease

  • Raza Alikhan, MD

      Affiliations

    • Department of Haematology, John Radcliffe Hospital, Oxford, UK
    • Corresponding Author InformationRequests for reprints should be addressed to Raza Alikhan, MD, Department of Haematology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK
    • ,
  • Alex C. Spyropoulos, MD

      Affiliations

    • Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM

References 

  1. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med. 1989;82:203–205
  2. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg. 1991;78:849–852
  3. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001;120:1964–1971
  4. Anderson FA, Tapson VF, Decousus H, et al. IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: a comparison with clinical study patient populations [Abstract]. Blood. 2003;102:1146
  5. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132:936–945
  6. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost. 2007;5:1610–1616
  7. Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119:145–155
  8. Cohen AT, Tapson VF, Bergmann JF, et al. ENDORSE Investigators Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–394
  9. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: ACCP evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:381S–453S
  10. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism (International Consensus Statement (guidelines according to scientific evidence)). Int Angiol. 2006;25:101–161
  11. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14–19
  12. Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1476–1486
  13. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146:278–288
  14. Ahmad HA, Geissler A, MacLelIan DG. Deep venous thrombosis prophylaxis: are guidelines being followed?. ANZ J Surg. 2002;72:331–334
  15. Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest. 2007;132:554–561
  16. Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res. 2003;112:203–207
  17. Prescott SM, Richards KL, Tikoff G, et al. Venous thromboembolism in decompensated chronic obstructive pulmonary disease (A prospective study). Am Rev Respir Dis. 1981;123:32–36
  18. Winter JH, Buckler PW, Bautista AP, et al. Frequency of venous thrombosis in patients with an exacerbation of chronic obstructive lung disease. Thorax. 1983;38:605–608
  19. Schönhofer B, Köhler D. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiration. 1998;65:173–177
  20. Akgun M, Meral M, Onbas O, et al. Comparison of clinical characteristics and outcomes of patients with COPD exacerbation with or without venous thromboembolism. Respiration. 2006;73:428–433
  21. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006;144:390–396
  22. Erelel M, Cuhadaroğlu C, Ece T, Arseven O. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2002;96:515–518
  23. Pek WY, Johan A, Stan S, et al. Deep vein thrombosis in patients admitted for exacerbation of chronic obstructive pulmonary disease. Singapore Med J. 2001;42:308–311
  24. Mispelaere D, Glerant JC, Audebert M, et al. Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations [French]. Rev Mal Respir. 2002;19:415–423
  25. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD (The Association of Non-University Affiliated Intensive Care Specialist Physicians of France). Am J Respir Crit Care Med. 2000;161:1109–1114
  26. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614–621
  27. Cohen AT, Davidson BL, Gallus AG, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–329
  28. Monreal M, Muñoz-Torrero JF, Naraine VS, et al. Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Am J Med. 2006;119:851–858
  29. Stein PD, Beemath A, Meyers FA, Olson RE. Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease. J Cardiovasc Med (Hagerstown). 2007;8:253–257
  30. Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm. 2006;63(20 Suppl 6):S16–S22
  31. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (Prophylaxis in Medical Patients with Enoxaparin Study Group). N Engl J Med. 1999;341:793–800
  32. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14:341–346
  33. Cohen AT, Turpie AG, Leizorovicz A, et al. PREVENT Medical Thromboprophylaxis Study Group Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vasc Med. 2007;12(2):123–127
  34. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006;22:31–38
  35. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. Presented at the Annual Meeting of the International Society of Thrombosis and Haemostasis, 2007. Abstract #O-S-001.
  36. Tapson VF, Hull RD, Schellong SM, et al. Consistent venous thromboembolism risk reduction by extended-versus standard-duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM Study [Abstract]. Blood. 2007;110:1863
  37. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968–974
  38. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? (Virchow's triad revisited). J Am Coll Cardiol. 1999;33:1424–1426
  39. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure (Collaborative Group on ACE Inhibitor Trials). JAMA. 1995;273:1450–1456
  40. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879
  41. Darze ES, Latado AL, Guimarães AG, et al. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest. 2005;128:2576–2580
  42. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26:115–117
  43. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415–3420
  44. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–262
  45. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol. 2001;54:810–816
  46. Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc. 2004;52:1299–1304
  47. Beemath A, Stein PD, Skaf E, et al. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006;98:793–795
  48. Darze ES, Latado AL, Guimarães AG, et al. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest. 2007;131:1838–1843
  49. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin) (The Prime Study Group). Haemostasis. 1996;26(Suppl 2):49–56
  50. Gårdlund B. Fatal pulmonary embolism in hospitalized non-surgical patients. Acta Med Scand. 1985;218:417–421
  51. Gärdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases (The Heparin Prophylaxis Study Group). Lancet. 1996;347:1357–1361
  52. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164:963–968
  53. King CS, Holley AB, Jackson JL, Shorr AF, Moores LK. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest. 2007;131:507–516
  54. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94:750–759
  55. Yalamanchili K, Sukhija R, Sinha N, et al. Efficacy of unfractionated heparin for thromboembolism prophylaxis in medical patients. Am J Ther. 2005;12:293–299

PII: S0002-9343(08)00707-9

doi: 10.1016/j.amjmed.2008.05.045

The American Journal of Medicine
Volume 121, Issue 11 , Pages 935-942 , November 2008

Article Tools

* Image Usage & Resolution